SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?

A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.


EoY 2022-LysoSENS

Week Two of our 2022 End of Year Campaign features LysoSENS (Clearing Waste Accumulations Out of Cells) – with a disease focus on Challenging Atherosclerosis. Also featuring videos from Life Noggin, AMA with Dr. Matthew O’Connor and Michael Rae.


New Breakthroughs in Clearing Out Brain Cell Plaques from the Inside

Research Info Tau is the major microtubule-associated protein (MAP) in mature neurons in the central nervous system. The MAPT (microtubule-associated protein tau) gene encodes for six splice variants that are highly soluble; their main function is interacting and stabilizing microtubules, along with other MAPs. The ability of tau to stabilize the microtubule is aided by …

Read more


A Small Molecule Approach to Removal of Toxic Oxysterols as a Treatment For Atherosclerosis

This research program has successfully spun-out into a company! Visit the Cyclarity Therapeutics website for more information on their transformative approach to atherosclerosis. SENS Research Foundation Research Center Principal Investigator: Matthew O’ConnorResearch Team: Amelia Anderson, Carolyn Barnes, Angielyn Campo, Anne Corwin, Sirish Narayanan Many diseases of aging are driven in part by the accumulation of “junk inside …

Read more


Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also


You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: